{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:51:25Z","timestamp":1787237485200,"version":"build-2736575974"},"reference-count":116,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations. (3) Results: Dosing regimens are proposed, together with monitoring recommendations and target anti-factor Xa ranges. (4) Conclusion: In a comprehensive summary detailed interdisciplinary dosing recommendations are described to provide a basis for safe and effective use of danaparoid.<\/jats:p>","DOI":"10.3390\/ph17121584","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:59:34Z","timestamp":1732528774000},"page":"1584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Danaparoid\u2014Consensus Recommendations on Its Clinical Use"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1741","authenticated-orcid":false,"given":"Rupert M.","family":"Bauersachs","sequence":"first","affiliation":[{"name":"Cardioangiology Center Bethanien, Vascular Center and Coagulation Center, Im Pr\u00fcfling 23, 60389 Frankfurt, Germany"},{"name":"Center for Vascular Research, Munich, Hochkalter Strasse 4a, 81547 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-7887","authenticated-orcid":false,"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[{"name":"Cardioangiology Center Bethanien, Vascular Center and Coagulation Center, Im Pr\u00fcfling 23, 60389 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Department Angiology and Haemostaseology, Vivantes Klinikum Friedrichsheim, Landsberger Allee 49, Friedrichshain, 10249 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Koster","sequence":"additional","affiliation":[{"name":"Department of Cardio-Anaesthesiology, Sana-Herzzentrum Cottbus GmbH, Leipziger Stra\u00dfe 50, 03048 Cottbus, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schindewolf","sequence":"additional","affiliation":[{"name":"Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Magnani","sequence":"additional","affiliation":[{"name":"Independent Researcher, 5345 MT Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ng, J.Y., D\u2019Souza, M., Hutani, F., and Choi, P. (2024). Management of Heparin-Induced Thrombocytopenia: A Contemporary Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164686"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory diagnosis of heparin-induced thrombocytopenia","volume":"41","author":"Warkentin","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_5","unstructured":"Shaz, B.H., Hillyer, C.D., and Reyes Gil, M. (2019). Chapter 104\u2014Heparin-Induced Thrombocytopenia. Transfusion Medicine and Hemostasis, Elsevier. [3rd ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.accpm.2020.03.012","article-title":"Diagnosis and management of heparin-induced thrombocytopenia","volume":"39","author":"Gruel","year":"2020","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_9","unstructured":"Floege, J., Johnson, R.J., and Feehally, J. (2010). CHAPTER 80\u2014Other Blood and Immune Disorders in Chronic Kidney Disease. Comprehensive Clinical Nephrology, Mosby. [4th ed.]."},{"key":"ref_10","unstructured":"Kitchens, C.S., Kessler, C.M., Konkle, B.A., Streiff, M.B., and Garcia, D.A. (2019). 27\u2014Parenteral Antithrombotic Agents. Consultative Hemostasis and Thrombosis, Elsevier. [4th ed.]."},{"key":"ref_11","first-page":"58","article-title":"Orgaran (Org 10172): Its pharmacological profile in experimental models","volume":"22","author":"Meuleman","year":"1992","journal-title":"Haemostasis"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gardini, C., Urso, E., Guerrini, M., van Herpen, R., de Wit, P., and Naggi, A. (2017). Characterization of Danaparoid Complex Extractive Drug by an Orthogonal Analytical Approach. Molecules, 22.","DOI":"10.3390\/molecules22071116"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1160\/TH05-07-0489","article-title":"Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004","volume":"95","author":"Magnani","year":"2006","journal-title":"Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0049-3848(96)00027-8","article-title":"Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia","volume":"81","author":"Vun","year":"1996","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-0037-1615190","article-title":"Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid","volume":"80","author":"Newman","year":"1998","journal-title":"Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.athoracsur.2016.06.068","article-title":"Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery","volume":"103","author":"Ronchard","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"gfaa142.P1077","DOI":"10.1093\/ndt\/gfaa142.P1077","article-title":"Persistence of circulating residual heparin in ESRD patients undergoing maintenance hemodialysis","volume":"35","author":"Bansal","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1055\/s-0038-1650717","article-title":"The use of heparinase improves the specificity of crossreactivity testing in heparin-induced thrombocytopenia","volume":"76","author":"Potzsch","year":"1996","journal-title":"Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1055\/s-0038-1656324","article-title":"The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia","volume":"68","author":"White","year":"1992","journal-title":"Thromb. Haemost."},{"key":"ref_20","first-page":"626a","article-title":"Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia and thrombosis: Effects on in-vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in-vitro cross-reactivity (XR) of danaparoid for HIT IgG","volume":"88","author":"Warkentin","year":"1996","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Greinacher, A., and Warkentin, T.E. (2013). Treatment of Heparin-Induced Thrombocytopenia: An Overview, CRC Press.","DOI":"10.3109\/9781841848617"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1055\/s-0038-1648491","article-title":"Heparin-associated thrombocytopenia: The antibody is not heparin specific","volume":"67","author":"Greinacher","year":"1992","journal-title":"Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/j.1538-7836.2008.03171.x","article-title":"Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes","volume":"6","author":"Krauel","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood.V73.6.1592.1592","article-title":"Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172","volume":"73","author":"Chong","year":"1989","journal-title":"Blood"},{"key":"ref_25","first-page":"394","article-title":"Heparin-induced thrombocytopenia and thrombosis syndrome: In vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin","volume":"114","author":"Keng","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1034\/j.1600-0609.2003.00105.x","article-title":"Danaparoid for heparin-induced thrombocytopenia: An analysis of treatment failures","volume":"71","author":"Kodityal","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00134-009-1464-x","article-title":"Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: Report of 12 cases","volume":"35","author":"Wolf","year":"2009","journal-title":"Intensive Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.thromres.2005.04.011","article-title":"Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and\/or coumarin explain the rapid shift in clinical practice during the 1990s","volume":"117","author":"Lubenow","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.thromres.2009.04.002","article-title":"Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia","volume":"124","author":"Elalamy","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MBC.0000000000000566","article-title":"Persistent heparin-induced thrombocytopenia: Danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report","volume":"28","author":"Horlait","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_31","first-page":"66","article-title":"Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849)","volume":"22","author":"Ofosu","year":"1992","journal-title":"Haemostasis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.1997.tb01667.x","article-title":"The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls","volume":"58","author":"Burgess","year":"1997","journal-title":"Eur. J. Haematol."},{"key":"ref_33","first-page":"550","article-title":"Influence of heparin and Org 10172 on tissue-type plasminogen activator plasma activity during rest and exercise","volume":"68","author":"Cohen","year":"1922","journal-title":"Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1160\/TH09-05-0306","article-title":"The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis","volume":"103","author":"He","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_35","unstructured":"Pifarre, R. (1997). Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. New Anticoagulants for the Cardiovascular Patient, Hanley & Belfus Inc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0049-3848(86)90002-2","article-title":"Placental transfer of Org 10172, a low-molecular weight heparinoid, in the awake late-pregnant guinea pig","volume":"44","author":"Peeters","year":"1986","journal-title":"Thromb. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.thromres.2009.06.006","article-title":"An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran)","volume":"125","author":"Magnani","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-2002-35284","article-title":"Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation","volume":"28","author":"Bauersachs","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0049-3848(87)90386-0","article-title":"Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats","volume":"48","author":"Hobbelen","year":"1987","journal-title":"Thromb. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1186\/cc6943","article-title":"Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats","volume":"12","author":"Iba","year":"2008","journal-title":"Crit. Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0741-5214(88)90315-1","article-title":"Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid","volume":"8","author":"Dryjski","year":"1988","journal-title":"J. Vasc. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1160\/TH06-04-0226","article-title":"Danaparoid sodium reduces ischemia\/reperfusion-induced liver injury in rats by attenuating inflammatory responses","volume":"97","author":"Harada","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_43","unstructured":"Nakahara, M., Yasuda, T., Taniguchi, J., Kakihama, Y., and Kanmura, Y. (2009). Efficacy of danaparoid on sepsis with DIC in patients admitted to the ICU. Proc. Am. Soc. Anesthesiol., A913."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Magnani, H.N. (2022). Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders. Anticoagulation\u2014Current Perspectives, IntechOpen.","DOI":"10.5772\/intechopen.103851"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12959-021-00362-y","article-title":"Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT","volume":"20","author":"Myllylahti","year":"2022","journal-title":"Thromb. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2125.1987.tb03100.x","article-title":"ORG 10172: A low molecular weight heparinoid anticoagulant with a long half-life in man","volume":"23","author":"Bradbrook","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.CIR.93.1.80","article-title":"Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture","volume":"93","author":"Gent","year":"1996","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0049-3848(87)90312-4","article-title":"Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis","volume":"45","author":"Cade","year":"1987","journal-title":"Thromb. Res."},{"key":"ref_49","first-page":"73","article-title":"Pharmacokinetic considerations on Orgaran (Org 10172) therapy","volume":"22","author":"Danhof","year":"1992","journal-title":"Haemostasis"},{"key":"ref_50","first-page":"1345","article-title":"Pharmacokinetics of KB-101","volume":"23","author":"Yasunaga","year":"1995","journal-title":"Jpn. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.ndt.a091694","article-title":"Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant","volume":"3","author":"Frei","year":"1988","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3918\/jsicm.16.67","article-title":"Pharmacokinetics of danaparoid sodium in patients undergoing continuous haemodiafiltration complicated by disseminated intravascular coagulation","volume":"16","author":"Nakano","year":"2009","journal-title":"Jpn. Soc. Intens. Care Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.thromres.2009.10.008","article-title":"A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis","volume":"125","author":"Magnani","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0039-1689740","article-title":"Intracerebral Hemorrhage: A Brief Evidence-Based Review of Common Etiologies, Mechanisms of Secondary Injury, and Medical and Surgical Management","volume":"6","author":"Sarma","year":"2019","journal-title":"J. Neuroanaesthesiol. Crit. Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1053-0770(97)90239-1","article-title":"Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: Role of adjunctive plasmapheresis","volume":"11","author":"Schmahl","year":"1997","journal-title":"J. Cardiothorac. Vasc. Anesth"},{"key":"ref_56","unstructured":"(2024, November 11). Danaparoid Sodium, Available online: https:\/\/go.drugbank.com\/salts\/DBSALT001136."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0037-1615946","article-title":"A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia","volume":"85","author":"Farner","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1055\/s-0037-1614355","article-title":"Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia","volume":"82","author":"Tardy","year":"1999","journal-title":"Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/01.STR.21.9.1289","article-title":"Large-dose infusions of heparinoid ORG 10172 in ischemic stroke","volume":"21","author":"Massey","year":"1990","journal-title":"Stroke"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-123-1-199507010-00001","article-title":"Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial","volume":"123","author":"Banga","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1378\/chest.115.6.1616","article-title":"Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia","volume":"115","author":"Tardy","year":"1999","journal-title":"Chest"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/BF01706210","article-title":"Heparin-induced thrombocytopenia type II: Successful use of Orgaran (ORG 10172) in intensive care patients","volume":"21","author":"Sohngen","year":"1995","journal-title":"Intensive Care Med."},{"key":"ref_64","first-page":"1","article-title":"Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? An Analysis of Case Reports","volume":"1","author":"Magnani","year":"2012","journal-title":"Open Access Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.thromres.2019.06.008","article-title":"Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia\u2014Need for a higher than recommended weight-based dosing","volume":"180","author":"Castelino","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/cc6119","article-title":"Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: A pilot study","volume":"11","author":"Hofstra","year":"2007","journal-title":"Crit. Care"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/ajkd.2002.36331","article-title":"Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients","volume":"40","author":"Polkinghorne","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"P371","DOI":"10.1186\/cc5531","article-title":"Orgaran\u00ae use in intensive care unit patients with heparin-induced thrombocytopenia and acute renal failure","volume":"11","author":"Magnani","year":"2007","journal-title":"Crit. Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/107602960100700409","article-title":"Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients","volume":"7","author":"Betz","year":"2001","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/bjs.1800790919","article-title":"Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine","volume":"79","author":"Leyvraz","year":"1992","journal-title":"Br. J. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3928\/0147-7447-19981001-11","article-title":"A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group","volume":"21","author":"Comp","year":"1998","journal-title":"Orthopedics"},{"key":"ref_72","first-page":"617","article-title":"Thromboprophylaxis in patients with hip fractures: A prospective, randomized, comparative study between Org 10172 and dextran 70","volume":"109","author":"Bergqvist","year":"1991","journal-title":"Surgery"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0038-1647468","article-title":"The effect of different anaesthetic techniques on the incidence of thrombosis following total hip replacement","volume":"65","author":"Hoek","year":"1991","journal-title":"Thromb. Haemost."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11916-019-0805-x","article-title":"Regional Anesthesia in Patients on Anticoagulation Therapies-Evidence-Based Recommendations","volume":"23","author":"Kaye","year":"2019","journal-title":"Curr. Pain. Headache Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/EJA.0000000000001600","article-title":"Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC\/ESRA guidelines","volume":"39","author":"Kietaibl","year":"2022","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.athoracsur.2019.10.076","article-title":"Mitigating the Risk: Transfusion or Reoperation for Bleeding After Cardiac Surgery","volume":"110","author":"Pasrija","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.athoracsur.2019.01.061","article-title":"Impact of Bleeding Revision on Outcomes After Left Ventricular Assist Device Implantation","volume":"108","author":"Angleitner","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"ref_78","first-page":"A223","article-title":"The use of danaparoid sodium in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary by-pass is detrimental","volume":"99","author":"Buys","year":"2003","journal-title":"Anesthesiology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1160\/TH04-06-0345","article-title":"Treatment of 51 pregnancies with danaparoid because of heparin intolerance","volume":"93","author":"Kreutzenbeck","year":"2005","journal-title":"Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/14397595.2019.1602241","article-title":"Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome","volume":"30","author":"Yoshihara","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0140-6736(12)60409-7","article-title":"Heparin-induced skin lesions","volume":"380","author":"Schindewolf","year":"2012","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/187152571302151217124957","article-title":"Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review","volume":"13","author":"Chaudhary","year":"2015","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_83","first-page":"307","article-title":"Successful pregnancy after pulmonary embolism and heparin-induced thrombocytopenia--Case report","volume":"40","author":"Plesinac","year":"2013","journal-title":"Clin. Exp. Obstet. Gynecol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12522-010-0056-3","article-title":"Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome","volume":"9","author":"Shimada","year":"2010","journal-title":"Reprod. Med. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-015-1309-0","article-title":"Guidance for the treatment and prevention of obstetric-associated venous thromboembolism","volume":"41","author":"Bates","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1055\/a-1132-0750","article-title":"Prevention of Venous Thromboembolism during Pregnancy and the Puerperium with a Special Focus on Women with Hereditary Thrombophilia or Prior VTE-Position Paper of the Working Group in Women\u2019s Health of the Society of Thrombosis and Haemostasis (GTH)","volume":"40","author":"Hart","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref_87","first-page":"309","article-title":"Prophylactic use of danaparoid sodium for deep-vein thromboembolism after cesarean section","volume":"57","author":"Tani","year":"2005","journal-title":"Adv. Obstet. Gynaecol."},{"key":"ref_88","first-page":"5","article-title":"Thromboembolic prophylaxis with danaparoid sodium for high thrombosis risk pregnant women after cesarean section","volume":"13","author":"Nohira","year":"2004","journal-title":"Jpn. J. Obstet. Gynaecol. Neonatal Haematol."},{"key":"ref_89","first-page":"501","article-title":"The contegra(R) valved heterograft conduit for right ventricular outflow tract reconstruction: A reliable solution","volume":"52","author":"Sfyridis","year":"2011","journal-title":"Hell. J. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e13099","DOI":"10.1111\/petr.13099","article-title":"Danaparoid reduces transplant-related mortality in stem cell transplantation for children","volume":"22","author":"Kato","year":"2018","journal-title":"Pediatr. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1182\/blood.V116.21.2123.2123","article-title":"The efficacy of prophylactic use of AT with unfractionated heparin or danaparoid sodium to prevent venous thromboembolism in children with acute lymphoblastic leukaemia","volume":"116","author":"Sakaguchi","year":"2010","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1365-2141.2012.09192.x","article-title":"Successful treatment with low-dose gemtuzumab ozogamicin in combination chemotherapy followed by stem cell transplantation for children with refractory acute myeloid leukaemia","volume":"158","author":"Yoshida","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgmr.2018.11.001","article-title":"Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy","volume":"18","author":"Kato","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"887S","DOI":"10.1378\/chest.08-0762","article-title":"Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Monagle","year":"2008","journal-title":"Chest"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000501818","article-title":"Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis","volume":"143","author":"Minakata","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_96","first-page":"848","article-title":"Immunological consequences following splenectomy in patients with liver cirrhosis","volume":"18","author":"Hirakawa","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12876-019-1140-8","article-title":"Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients","volume":"19","author":"Hayashi","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12876-017-0668-8","article-title":"Portal vein thrombosis in liver cirrhosis: Incidence, management, and outcome","volume":"17","author":"Fujiyama","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.13840","article-title":"Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study","volume":"53","author":"Hayama","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1111\/petr.12450","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition","volume":"19","author":"Sakamoto","year":"2015","journal-title":"Pediatr. Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/bmt.2016.270","article-title":"Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"52","author":"Machida","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/pbc.22645","article-title":"Danaparoid as the prophylaxis for hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in childhood hematological malignancy","volume":"55","author":"Sakaguchi","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MPH.0000000000002404","article-title":"Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia","volume":"44","author":"Yamada","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Carre, J., Guerineau, H., Le Beller, C., Mauge, L., Huynh, B., Nili, R., Planquette, B., Clauser, S., Smadja, D.M., and Helley, D. (2021). Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series. Front. Med., 8.","DOI":"10.3389\/fmed.2021.713649"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1055\/a-1333-4688","article-title":"Contrast between Prevalence of HIT Antibodies and Confirmed HIT in Hospitalized COVID-19 Patients: A Prospective Study with Clinical Implications","volume":"121","author":"Delrue","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/bjh.17619","article-title":"Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT)","volume":"195","author":"Ramdeny","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/jth.15346","article-title":"Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)","volume":"19","author":"Thaler","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2022.03.026","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination","volume":"214","author":"Langerak","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.15239","article-title":"The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease","volume":"19","author":"Lisman","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00381-004-0962-y","article-title":"Arterio-embolic ischemic stroke in children with moyamoya disease","volume":"21","author":"Horn","year":"2005","journal-title":"Childs Nerv. Syst."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/bloodadvances.2019001315","article-title":"New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT","volume":"4","author":"Elfeky","year":"2020","journal-title":"Blood Adv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: Theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/VHRM.S197732","article-title":"Splanchnic Vein Thrombosis: Current Perspectives","volume":"15","author":"Valeriani","year":"2019","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor\u2019s Choice\u2014European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:39:07Z","timestamp":1760114347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":116,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ph17121584"],"URL":"https:\/\/doi.org\/10.3390\/ph17121584","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}